News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Securities News, Articles and Videos with Contenting
Securities news and articles provide information on the stock market, investments, and other financial matters. They often include commentary and analysis from financial experts. Videos can also provide helpful information on financial matters, such as stock market trends, investment strategies, and economic news. Reading securities news and watching videos can help investors stay informed and make better decisions about their investments.
Is Vodafone Idea Rescue 2.0 Sufficient? Expert Weighs In
Balaji Subramanian, vice president of research at IIFL Securities, said he won't be surprised if Vodafone Idea asks for another equity conversion 18–24 months down the line as cash flow issues crop up. The expert expects debt raise of Rs 25,000 crore by the telecom operator soon.
'Buy' PTC Industries Maintains ICICI Securities, Sees 34% Upside - Here's Why
Aeroalloy Technologies Ltd., a wholly-owned subsidiary of PTC Industries Ltd., has received a significant long-term order from Safran Aircraft Engines, entailing supply of seven cast aero-engine components, utilising both titanium and superalloys for CFM’s advanced LEAP-1A and LEAP-1B engines. This collaboration positions ATL as the only Indian company supplying cast (aeroengine) components in Ti and superalloys.
SC affirms SEC power to accredit external auditors - BusinessWorld Online
THE SUPREME COURT (SC) has affirmed the power of the Securities and Exchange Commission (SEC) to accredit external auditors of companies that issue registered securities and own secondary licenses, reversing two decisions it issued earlier. In a resolution promulgated on Jan. 28 and released on Monday, the full court upheld the validity of the rules […]
SEC Grants Deadline Extension for 56-1 One Report to Earthquake-Affected Listed and Issuing Companies - Thailand Business News
Bangkok faced an earthquake on March 28, 2025, affecting numerous listed companies. The Securities and Exchange Commission is permitting impacted companies to apply for deadline extensions for their reports.
Allot to Present at the LD Micro Invitational XV Conference on April 10, 2025 - ForexTV
Hod Hasharon, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of innovative security-as-a-service (SECaaS) and network intelligence solutions for communication service providers and enterprises, today announced that it will be participating at the 15th Annual LD Micro Invitational investor conference taking place in New York on April 9th and 10th, 2025. The event is expected to feature leading small-cap companies presenting in half-hour increments, as well as private one-on-one meetings. Mr. Eyal Harari, CEO of Allot, will be presenting to investors on Thursday, April 10 between 12:00-12:25pm in Track 1. Interested parties are invited to register to watch the presentation virtually through a link on Allot’s website. In addition, management will also be available for one-on-one meetings with investors throughout that day at the conference. To schedule a meeting with management, please contact an LD Micro representative or email a request to the investor relations team at allot@ekgir.com About Allot Allot Ltd. (NASDAQ: ALLT, TASE: ALLT) is a provider of leading innovative converged cybersecurity solutions and network intelligence for service providers and enterprises worldwide, enhancing value to their customers. Our solutions are deployed globally for network-native cybersecurity services, network and application analytics, traffic control and shaping, and more. Allot’s multi-service platforms are deployed by over 500 mobile, fixed and cloud service providers and over 1000 enterprises. Our industry-leading network-native security-as-a-service solution is already used by many millions of subscribers globally. Allot. See. Control. Secure. For more information, visit www.allot.com Safe Harbor Statement This release contains forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements set forth in such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our accounts receivables, including our ability to collect outstanding accounts and assess their collectability on a quarterly basis; our ability to meet expectations with respect to our financial guidance and outlook; our ability to compete successfully with other companies offering competing technologies; the loss of one or more significant customers; consolidation of, and strategic alliances by, our competitors; government regulation; the timing of completion of key project milestones which impact the timing of our revenue recognition; lower demand for key value-added services; our ability to keep pace with advances in technology and to add new features and value-added services; managing lengthy sales cycles; operational risks associated with large projects; our dependence on fourth party channel partners for a material portion of our revenues; and other factors discussed under the heading "Risk Factors" in the Company's annual report on Form 20-F filed with the Securities and Exchange Commission. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. CONTACT: Seth Greenberg Allot +972 54 922 2294 sgreenberg@allot.com Ehud Helft Allot Investor Relations +1 212 378 8040 allot@ekgir.com
Li Auto Inc. March 2025 Delivery Update - ForexTV
BEIJING, China, April 01, 2025 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 36,674 vehicles in March 2025, representing a year-over-year increase of 26.5%. This brought the Company’s first-quarter deliveries to 92,864, an increase of 15.5% year-over-year. As of March 31, 2025, Li Auto’s cumulative deliveries reached 1,226,736. Li Auto has remained the sales champion among Chinese automotive brands in the RMB200,000 and above NEV market for twelve consecutive months. As a key contributor to the Company’s rapid path to profitability and its breakthrough in surpassing the RMB100 billion revenue mark, the Li L series is on track to soon achieve a new milestone with the delivery of its 1,000,000th vehicle. The new Li MEGA Ultra, featuring upgraded autonomous driving configurations, is already open for reservations. Further exciting updates to the Li MEGA model are expected to be unveiled at Auto Shanghai 2025. In March, Li Auto became the world’s first automaker to commit to open-sourcing its proprietary OS for smart vehicles, Li Halo OS. Additionally, the Company expects its next-generation proprietary autonomous driving architecture, MindVLA, to accelerate the adoption of autonomous driving technologies, extending their benefits to a wider range of users. As of March 31, 2025, the Company had 500 retail stores in 150 cities, 502 servicing centers and Li Auto-authorized body and paint shops operating in 225 cities. The Company also had 2,045 super charging stations in operation equipped with 11,038 charging stalls in China. About Li Auto Inc. Li Auto Inc. is a leader in China’s new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric vehicles. Its mission is: Create a Mobile Home, Create Happiness (创造移动的家,创造幸福的家). Through innovations in product, technology, and business model, the Company provides families with safe, convenient, and comfortable products and services. Li Auto is a pioneer in successfully commercializing extended-range electric vehicles in China. While firmly advancing along this technological route, it builds platforms for battery electric vehicles in parallel. The Company leverages technology to create value for users. It concentrates its in-house development efforts on proprietary range extension systems, innovative electric vehicle technologies, and smart vehicle solutions. The Company started volume production in November 2019. Its current model lineup includes Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, Li L8, a six-seat premium family SUV, Li L7, a five-seat flagship family SUV, and Li L6, a five-seat premium family SUV. The Company will continue to expand its product lineup to target a broader user base. For more information, please visit: https://ir.lixiang.com. Safe Harbor Statement This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “targets,” “likely to,” “challenges,” and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”) and The Stock Exchange of Hong Kong Limited (the “HKEX”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Auto’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Auto’s strategies, future business development, and financial condition and results of operations; Li Auto’s limited operating history; risks associated with extended-range electric vehicles and high-power charging battery electric vehicles; Li Auto’s ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Auto’s ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Auto’s ability to compete successfully; Li Auto’s ability to build its brand and withstand negative publicity; cancellation of orders for Li Auto’s vehicles; Li Auto’s ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Auto’s filings with the SEC and the HKEX. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: Li Auto Inc.Investor RelationsEmail: ir@lixiang.com Christensen AdvisoryRoger HuTel: +86-10-5900-1548Email: Li@christensencomms.com
Treatment.com AI and Aiyibotong collaborate to explore commercial opportunities for Clinical Decision Support in China and Far East - ForexTV
Market for Clinical Decision Support (CDSS) in China is ~US$600 million by 2030Aiyibotong has installed systems in >200 healthcare institutions in ChinaAiyibotong and Treatment.com AI both using proprietary artificial intelligence (AI) and Machine Learning (ML) platformsCo-marketing opportunities in ChinaCombining Aiyibotong’s CDSS with Treatment AI's Global Library of Medicine will look to create further differentiation and increased market share for Aiyibotong in the China and Far East markets VANCOUVER, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has recently signed a Collaborative Agreement on with Beijing Aiyi Botong Information Technology Ltd Limited (“Aiyibotong”). Each organization has a focus in providing enhanced clinical decision support for both healthcare professionals and patients, using innovative technologies including AI and machine learning. Aiyibotong and Treatment are exploring complementary technology synergies, including Treatment’s proprietary Global Library of Medicine (“GLM”), to enhance patient support in China and other Far East countries. Investment in Digital Health in China is expected to reach US$45 billion in 2025, including AI investment Digital Health - China | Statista Market Forecast driven by market expansion and strategic government investments. As examples, according to Horizon Grand View Research, the clinical decision support (CDSS) market in China alone is expected to double between 2024 and 2030, with a market size of ~US$600 million in 2030 China Clinical Decision Support Systems Market Size & Outlook, 2030 Treatment is partnering with Aiyibotong, a China based healthcare information technology company focused on providing clinical decision supporting solutions (CDSS) for medical professionals in both large hospitals as well as clinics. Its CDSS has been developed on proprietary AI technologies, natural language processing (NLP) as well as machine learning algorithms and knowledge graph. Since its establishment in 2019, it has installed its CDSS systems in more than 200 healthcare institutions. The company is currently expanding its product portfolio to cover broader clinical quality assurance systems including Electronic Medical Record (EMR) QA, Venous Thromboembolism (VTE) Risk Management and Multidisciplinary Team (MDT) assistants. The envisaged areas of collaboration include: Aiyibotong assisting Treatment in localization of its Global Library of Medicine (GLM) content and alignment with Chinese medical consensus;Aiyibotong licensing Treatment technology and integration with its’ CDSS platformCo-marketing in China, targeting healthcare institutions and universities;Co-developing an AI based CDSS for the global market, combining Aiyibotong’s value of 10 years of experience in the sector and accumulated data and know-how, together with Treatment’s technology and global medical professionals. The Agreement was signed on 19th February 2025 and there are no costs associated with this Agreement. Treatment’s Global Library of Medicine (GLM) enables healthcare professionals to capture a patient’s presenting symptoms, past medical history and through AI and smart proprietary algorithms, formulate the most likely diagnosis and suggest the most important tests/exams that should be performed. This history can then be shared with the patient’s healthcare professional in real time and also programmed to help with triaging patients more efficiently. The Agreement was signed on 19th February 2025 and there are no costs associated with this Agreement. Treatment and Aiyibotong have already started to explore mutually beneficial opportunities through China and the Far East regions. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “We look forward to working with Aiybotong to expand the GLM to new languages and opportunities in Asia and the Far East. Amongst the solutions we believe can augment Aiyibotong’s product lines, our new AI voice agent/assistant speaking in regional languages and with local dialects, can help onboard and triage marginalized and underserved patients in the community.” Chenjin Liu, General Manager of Aiyibotong comments: “Aiyibotong is in the process of adopting new LLM technologies in our CDSS product lines and will use the ‘knowledge + data’ hybrid model to drive our system so that the LLM can make our product more AI empowered while our existing knowledge graph and expert system will effectively limit the hallucination in LLM. We’re excited to collaborate with Treatment as their Global Library of Medicine can be a great value add to enhance our expert system. In addition to the China market, we see this hybrid model driven CDSS can be a global product.” About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services, go to: www.treatment.com or email: info@treatment.com About Aiyibotong Aiyibotong is a Chinese company specialized in developing and marketing Clinical Decision Support solutions to healthcare institutions. Its CDSS is currently based on a natural language process model and knowledge graph, and in the process of adoption of LLM technologies. Its CDSS provides clinical suggestions for over 9,000 diseases. Aiyibotong’s CDSS is currently integrated with most of the main Chinese HIS and EMR systems installed in both large hospitals and small clinics. To learn more about Aiyibotong’s products and services, go to: www.aiyibotong.com or email: support@aiyibotong.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
'Buy' Hindustan Aeronautics Maintains ICICI Securities On Strong Orderbook, Relatively Inexpensive Valuation
Hindustan Aeronautics Ltd. has clocked revenue of Rs 304 billion in FY25 (versus Rs 303.8 billion in FY24). Key points: Revenue was ~6% below our estimate of Rs 322.4 billion, mainly because of shortfall in delivery of ALH-Dhruv and other manufacturing revenue. Order inflow for FY25 was Rs 1,195 billion – this includes manufacturing order of Rs 1,020 billion and repair and overhaul order inflow of Rs 175 billion.